Artículo
Blood biomarkers associated to complete pathologicalresponse on NSCLC patients treated with neoadjuvantchemoimmunotherapy included in NADIM clinical trial
Autor/es | Laza-Briviesca, Raquel
Cruz Bermúdez, Alberto Nadal, Ernest Insa, Amelia García Campelo, María del Rosario Huidobro, Gerardo Bernabé-Caro, Reyes Provencio, Mariano |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2021-07-14 |
Fecha de depósito | 2022-12-05 |
Publicado en |
|
Resumen | Background:Immunotherapy is being tested in early-stage non-small cell lungcancer (NSCLC), and achieving higher rates of complete pathological responses(CPR) as compared to standard of care. Early identification of CPR ... Background:Immunotherapy is being tested in early-stage non-small cell lungcancer (NSCLC), and achieving higher rates of complete pathological responses(CPR) as compared to standard of care. Early identification of CPR patients hasvital clinical implications. In this study, we focused on basal peripheral immunecells and their treatment-related changes to find biomarkers associated toCPR.Methods:Blood from 29 stage IIIA NSCLC patients participating in the NADIMtrial (NCT03081689) was collected at diagnosis and post neoadjuvant treatment.More than 400 parameters of peripheral blood mononuclear cells (PBMCs) phe-notype and plasma soluble factors were analyzed.Results:Neoadjuvant chemoimmunotherapy altered more than 150 immuneparameters. At diagnosis, 11 biomarkers associated to CPR were described, withan area under the ROC curve>0.70 andp-value<.05. CPR patients had sig-nificantly higher levels of CD4+PD-1+cells, NKG2D, and CD56 expression onT CD56 cells, intensity of CD25 expression on CD4+CD25hi+cells and CD69expression on intermediate monocytes; but lower levels of CD3+CD56–CTLA-4+cells, CD14++CD16+CTLA-4+cells, CTLA-4 expression on T CD56 cells andlower levels of b-NGF, NT-3, and VEGF-D in plasma compared to non-CPR. Posttreatment, CPR patients had significantly higher levels of CD19 expression on Bcells, BCMA, 4-1BB, MCSF, and PARC and lower levels of MPIF-1 and Flt-3L inplasma compared to non-CPR.Conclusions:Patients achieving CPR seem to have a distinctive peripheralblood immune status at diagnosis, even showing different immune response totreatment.TheseresultsreinforcethedifferentbiologybehindCPRandnon-CPRresponses. |
Agencias financiadoras | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) CD19/00170; PI19/01652 European Commission. Fondo Social Europeo (FSO) PEJ16/MED/AI-1972; PEJD-2018-PRE/SAL-8641; PEJD-2019-PRE/BMD-17006 Programa Marco Horizonte 2020 CLARIFY 875160 Instituto de Salud Carlos III CD19/00170; PI19/01652 Ministerio de Ciencia e Innovacion RTC2017-6502-1; RTC2019-007359-1 Grupo Español de Cáncer de Pulmón |
Identificador del proyecto | CD19/00170
PI19/01652 PEJ16/MED/AI-1972 PEJD-2018-PRE/SAL-8641 PEJD-2019-PRE/BMD-17006 CLARIFY 875160 CD19/00170 PI19/01652 RTC2017-6502-1 RTC2019-007359-1 |
Cita | Laza-Briviesca, R., Cruz Bermúdez, A., Nadal, E., Insa, A., García Campelo, M.d.R., Huidobro, G.,...,Provencio, M. (2021). Blood biomarkers associated to complete pathologicalresponse on NSCLC patients treated with neoadjuvantchemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine, 11 (7), e491. https://doi.org/10.1002/ctm2.491. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Blood biomarkers associated to ... | 3.067Mb | [PDF] | Ver/ | |